

BEAT Meth: delivering data-driven and accessible methamphetamine treatment

Scott Simpson, MD, MPH
Alia Al-Tayyib, PhD
Katherine Camfield, MD, MPH
Deborah Rinehart, PhD
Ryan Loh, PhD
Anthony Reedy, MPH
Chelsea Wolf, MD

BEATMeth



DENVER HEALTH™

est. 1860

FOR LIFE'S JOURNEY



ASAM Annual Conference, April 15, 2023

Disclosure Information (Required)

- ◆ Scott Simpson, MD MPH
 - ◆ Royalties from Taylor & Francis unrelated to current content
- ◆ Katherine Camfield, MD MPH
 - ◆ No disclosures
- ◆ Alia Al-Tayyib, PhD
 - ◆ No disclosures
- ◆ Deborah Rinehart, PhD
 - ◆ No disclosures

Agenda

- ◆ 0-20: The BEAT Meth approach to treating methamphetamine-induced psychotic disorder in health systems (Simpson)
- ◆ 20-40: What is methamphetamine-induced psychotic disorder? Results from an expert panel (Camfield)
- ◆ 40-60: Patient experiences in ED and perspectives on treatment. Results from a qualitative study (Rinehart)
- ◆ 60-75: Testing a new treatment paradigm: The BEAT Meth RCT (Al-Tayyib)

Learning Objectives

- ◆ Understand barriers to effective, equitable treatment for methamphetamine addiction
- ◆ Describe diagnostic criteria for methamphetamine-induced psychotic disorder
- ◆ Describe patient's perspectives on barriers to entering treatment for methamphetamine addiction
- ◆ Apply the above findings in patient case scenarios

The BEAT Meth Approach to Treating Methamphetamine-Induced Psychotic Disorder in Health Systems

Scott Simpson, MD, MPH
scott.Simpson@dhha.org

BEATMeth



DENVER HEALTH™


est. 1860

FOR LIFE'S JOURNEY



ASAM Annual Conference, April 15, 2023



Drug Overdose Deaths in Colorado



A Western Epidemic

Meth-involved Overdose Deaths

Heroin-involved Overdose Deaths





Case

A 30 year-old male is brought in by police after he was found causing a disruption in a grocery store: he was yelling at customers and throwing items off the shelves. Because he was disorganized and “manic,” police brought him to the ED.

In the ED, you see the patient has about 6 similar prior ED visits related to methamphetamine use. He receives midazolam and olanzapine, then sleeps for 12 hours. Upon awaking, he states he does not recall the events precipitating his visit. He is homeless, “so people cannot find me.” He denies suicidal or violent ideation.

Case


What is your recommended disposition?

- A. Admission to inpatient psychiatry
- B. Admission to inpatient medicine
- C. Admission to withdrawal management (eg, ASAM level 3.2)
- D. Discharge

Anything that might change your mind?


The Usual

Disposition after Methamphetamine-related ED visit




ED Departure Transferred Admitted Other

ED Suboxone/Methadone Inductions



Meth Psychosis and Epidemiology

Psychosis After Sobriety




- Psychosis in 40% of methamphetamine users
- High rates of persistent psychosis after use: 10-30% after 6 months
- Many patients diagnosed with schizophrenia

Pilot: Beginning Early and Assertive Treatment for Methamphetamine Psychosis

<i>Goal</i>	<i>Implementation</i>
Early recognition and disposition planning	Decision on disposition by hour 6 of ED visit
Early treatment	<ul style="list-style-type: none"> • Antipsychotic • Long-acting benzodiazepine • As needed benzodiazepine • Urine acidification • Double meal portions • Monitored detoxification
Enhanced recovery environment	Anticipate 48-72 hour stay
Improved connection to follow-up care	<ul style="list-style-type: none"> • Dedicated addiction counseling visit • Collaboration with Crystal Meth Anonymous • Enrollment in contingency management

BEAT Meth Pilot Outcomes



Vague & Inconsistent Diagnosis
Use

Lack of MIP Definition

Barriers

Community Partners

Challenging Patient Presentation

Patient Follow-Up

Aim 1: Evaluate and optimize the treatment pathway for patients presenting to the ED with methamphetamine use disorder.

- Develop standard work
- Build community partnerships
- Improve likelihood of patients entering treatment
- Create sustainable clinical workflows

Aim 2: Evaluate a linkage-to-care intervention to engage and retain patients in treatment.

- Test a new case management intervention versus usual care in a randomized clinical trial with 182 subjects

Aim 3: Develop a methamphetamine use disorder continuum of care model to measure progression of patients with methamphetamine use disorder.

- Create a framework to monitor the prevalence of methamphetamine use disorder
- Monitor patients' progress in treatment
- Direct resources to at-risk populations

Lean Process Meetings

Dec '21

- Lean fundamentals training—including for community partners

Jan '22

- Current state
- Stakeholder engagement

Feb '22

- Standard work
- Communication strategies

Mar '22

- Epic build
- Considering barriers to access

Apr '22

- Reviewed challenges of identifying patients
- Expand protocol to additional services

May '22

- **Side events: outpatient services and CARES**
- New outpatient protocol

Sep '22

- New system for identifying patients
- Implementation of pathway in different hospital areas


BEAT Meth Current State Process

Changes made during our work in GREEN




Is Methamphetamine Likely Present?

Encounters By Service (Aug '22-Jan '23)



BEAT Meth Protocol Encounters



Easier Treatment Entry

- Weds @ Noon
- Individual intakes are Tues and Thursday

Next Steps

- Electronic referrals
- Staff training

WANT TO STOP USING METH?

Come to Pavilion K on the main DH campus, any Wednesday at noon. Check in at the desk.

We can help. Learn about treatment and get started right away. No waiting. We offer

- Contingency management—win money
- Addiction, mental health, and medical treatment

DH providers: If able, it is helpful (but not necessary) to send an Epic message Wendi Hoag to alert OBHS of referral



BEATMeth



BEAT Meth

LeanAcademy@dhha.org
DHquest
MesaVerde

BLAKE

Final Takeaways/Summary

- ◆ Methamphetamine addiction is treatable.
- ◆ Provider awareness is a significant barrier.
- ◆ Evidence-based treatment needs to be accessible.
- ◆ Scaling up is hard.

Case

An 18-year-old homeless woman presents to the ED with suicidal ideation. She describes that “people are chasing her” and “I’m hearing voices” that make her want to die. She is accompanied by a female friend who states the patient used methamphetamine about 6 hours ago.

The patient receives a dose of risperidone and clonazepam, her symptoms improve, and she engages in crisis and discharge planning. She is disinterested in substance treatment, “I don’t use methamphetamine.” She asks about seeing someone for birth control.

Case

You decide the patient is able to discharge. Which of these interventions are indicated? (Pick any that you feel apt.)

- A.** A short-term course of risperidone
- B.** Referral to a primary care provider, because you think she is most likely to follow-up there
- C.** Referral to a specialized addiction treatment program
- D.** Referral to withdrawal management

Questions/Comments?



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

BEATMeth



References

- Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. *CNS Drugs*. 2014;28(12):1115-1126.
- Grelotti DJ, Kanayama G, Pope HG Jr. Remission of persistent methamphetamine-induced psychosis after electroconvulsive therapy: presentation of a case and review of the literature. *Am J Psychiatry*. 2010;167(1):17-23.
- Hedegaard, H., Bastian, B. A., Trinidad, J. P., Spencer, M. R., & Warner, M. (2019). Regional Differences in the Drugs Most Frequently Involved in Drug Overdose Deaths: United States, 2017. *National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System, 68(12), 1–16.*
- Akiyama K. Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence. *Ann N Y Acad Sci*. 2006;1074:125-134.
- Simpson SA, Wolf C, Loh RM, Camfield K, Rylander M. Evaluation of the BEAT Meth Intervention for Emergency Department Patients with Methamphetamine Psychosis. *J Addict Med*. 2023;17(1):67-73.

What is methamphetamine-induced psychotic disorder?

Results from an expert panel

Katherine Camfield, MD, MPH
Katherine.camfield@dhha.org

BEATMeth



DENVER HEALTH™

est. 1860

FOR LIFE'S JOURNEY



ASAM Annual Conference, April 15, 2023

Learning Objectives

- ◆ Understand how the Delphi Method can be used to develop an expert diagnostic consensus
- ◆ Define the diagnosis of methamphetamine-induced psychotic disorder

Challenges in MIP Diagnosis

- ◆ “..the severity of psychotic symptoms, including the negative ones observed in MA psychosis and schizophrenia are almost the same.”
- ◆ “...no differences in positive psychotic symptoms between the two groups.”
- ◆ 38% of inpatients diagnosed with MIP were diagnosed with schizophrenia within 7 years
- ◆ Treatments are very different!

Existing Definitions for MIP

◆ DSM-5

- ◆ Symptoms are not “substantially in excess of what would be expected”
- ◆ psychotic symptoms do not “persist for at least one month after the cessation of intoxication or acute withdrawal”
- ◆ Do not occur during delirium

◆ ICD-10

- ◆ “Schizophrenia is a disorder that is characterized by at least one psychotic symptom..that last[s] for more than a month, and is not related to drug intoxication or withdrawal”

◆ Other Authors

- ◆ “A MA-induced psychotic disorder is diagnosed when the observed psychotic symptoms exceed the known and expected effects of intoxication or withdrawal from MA.”

The Value of a Diagnosis

Reliable identification

Public Health Surveillance

Treatment Planning

Policy Making

Risk/benefit analysis

Therapeutic Intervention

Our Goal


- ◆ How do you diagnose methamphetamine-induced psychosis (MIP)?
 - ◆ When do you diagnose MIP instead of methamphetamine intoxication?
 - ◆ When do you diagnose MIP instead of a primary psychotic disorder?
 - ◆ What diagnostic criteria might be used to define MIP
 - ◆ Describe characteristics of MIP vs. alternative diagnoses
 - ◆ Time frame since last use? Quality of symptoms? Prior treatment history? Response to prior treatment? Concurrent diagnoses?
- ◆ Product: Produce Specific criteria, or at least guidance to inform diagnostic criteria

Delphi Method

- ◆ Iterative feedback to develop consensus
- ◆ Standing monthly meetings for 3-4 months
- ◆ Communication between meetings
- ◆ Literature search and resources will be made available to the group
- ◆ A priori consensus defined as $\geq 80\%$ of respondents in agreement

Literature Review

Articles organized and saved in Zotero for group access



Panelist Inclusion Criteria

- ◆ At least 5 years of experience working with patients who are using methamphetamine and still seeing at least 3pts/wk
- ◆ Board certification in relevant specialty
- ◆ Review of CV and application by the leadership team, who will rate participants by consensus per Colton 2004 as 1=“Not useful,” 2=“Moderately useful,” or “3=Very useful”
 - ◆ Participants scoring 3 are included
 - ◆ Participants scoring 2 are considered if their inclusion would add experiential diversity to the panel (after accepting 3’s)

Timeline



Orientation

• September 1, 2022

Round 1 Survey

Round 1 Meeting

• October 11, 2022

Round 2 Survey

Round 2 Meeting

• November 15, 2022

Round 3 Survey

Round 3 Meeting

• January 12, 2023 (final meeting)

Round 1

Survey

- ◆ Thoughts on timing since last use
- ◆ How do you apply the diagnosis when patient also intoxicated?
- ◆ Sxs more suggestive of MIP?
- ◆ Considerations on patient history
- ◆ Considerations on comorbid psychiatric diagnoses

Meeting

- ◆ Morning and Evening meetings
- ◆ Group check-in and feedback
- ◆ Discussion of results
 - ◆ Themes within responses
 - ◆ Larger questions based on themes
- ◆ Suggestions for criteria

Round 2

Survey

- ◆ Reasons developing MIP diagnosis is important (Likert scale)
- ◆ Hours since last use patient is still intoxicated with meth?
- ◆ Acute vs. Chronic MIP
- ◆ Voting on specific symptoms

Meeting

- ◆ Morning and evening meeting
- ◆ Group check-in and feedback
- ◆ Review of survey results
- ◆ Initial proposal of criteria based on these results
- ◆ Discussion

Round 3

Survey

- ◆ Panelists have the opportunity to vote and/or comment on the following:
 - ◆ Specific criteria deduced from prior surveys and meetings
 - ◆ Priorities for next steps
 - ◆ Feedback on this consensus process

Meeting

- ◆ Single meeting time
- ◆ Final diagnostic criteria presented!
 - ◆ Acute and Persistent Meth-Induced Psychotic Disorder (next slide)
- ◆ Review of Demographics and future priorities
- ◆ Future involvement

Acute Methamphetamine-Induced Psychotic Disorder (AMIPD)

Acute MIPD is a clinical presentation of psychosis that emerges shortly after methamphetamine use

- A. There is evidence of recent methamphetamine use based on one of the following:
 1. Report by patient or informant of recent methamphetamine use
 2. Positive toxicology test
 3. Clinical presentation of methamphetamine intoxication or withdrawal

AMIPD Continued

- B. The presence of any of the following psychotic symptoms:
 - 1) Persecutory or paranoid delusions
 - 2) Auditory hallucinations
 - 3) Visual hallucinations
 - 4) Parasitosis, including with tactile hallucinations
 - 5) Tactile hallucinations, without parasitosis

- C. The psychotic symptoms cause clinically significant distress, impairment, or dangerousness

Persisting Methamphetamine-Induced Psychotic Disorder (PMIPD)

Persisting MIPD is a presentation of psychosis due to methamphetamine use in which psychosis persists beyond the initial period of intoxication or withdrawal. Persisting MIPD should be considered whenever a patient with psychosis has a history of methamphetamine use.

- A. The patient has a history of methamphetamine use.
- B. The onset of symptoms occurred during a period of methamphetamine use and persists after the patient has stopped using.
- C. The psychotic symptoms cause clinically significant distress or impairment.

PMIPD continued

D. Two timeframes describe the course of the disorder:

- 1) **Subacute PMIPD** describes symptoms persisting after the period of acute intoxication or withdrawal until one month of abstinence from methamphetamine. Psychotic symptoms likely to indicate subacute PMIPD:
 - i. Persecutory or paranoid delusions
 - ii. Auditory hallucinations
 - iii. Visual hallucinations
 - iv. Parasitosis, including with tactile hallucinations
 - v. Tactile hallucinations, without parasitosis

- 2) **Chronic PMIPD** describes symptoms persisting after one month of sobriety from methamphetamine. No specific psychotic symptoms differentiate PMIPD from those of primary psychotic disorders.

Priorities for Next Steps

	High or Very High Priority
Studying the likelihood of progression from Acute MIPD to Persisting MIPD	86%
Describing the validity of the proposed diagnoses	77%
Identifying the best medication treatments for MIPD	77%
Describing psychometric reliability of the proposed diagnoses	73%
Defining the time range of acute versus persisting disorder	59%
Identifying the best psychotherapeutic treatments for MIPD	55%
Describing biological predictors of MIPD	41%
Describing psychological predictors of MIPD	36%
Describing social predictors of MIPD	32%

Group Feedback

	Agree	Strongly Agree
It was easy to communicate with other panelists	50%	50%
It was easy to Communicate with panel leaders	23%	73%
I was able to get process questions answered to my satisfaction	27%	68%
The literature review was accessible	27%	68%
I reviewed scientific literature related to this panel	41%	55%
Online materials (eg, slide decks) were accessible	32%	50%
The online web meetings were accessible.	23%	48%
I felt my opinion was respected in this process	27%	73%
I feel that I contributed to the work and product of the group	36%	59%

What's Next?



Publication



Dissemination



Multi-site collaborations?

- Use of MIPD screening items
- Application of treatment protocols
- Validation of diagnosis

Questions/Comments?

Katherine.camfield@dhha.org



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

BEATMeth



References

1. Srisurapanont, Manit, et al. “Comparisons of Methamphetamine Psychotic and Schizophrenic Symptoms: A Differential Item Functioning Analysis.” *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, vol. 35, no. 4, 2011, pp. 959–964., <https://doi.org/10.1016/j.pnpbp.2011.01.014>.
2. Medhus, Sigrid, et al. “A Comparison of Symptoms and Drug Use between Patients with Methamphetamine Associated Psychoses and Patients Diagnosed with Schizophrenia in Two Acute Psychiatric Wards.” *Psychiatry Research*, vol. 206, no. 1, 2013, pp. 17–21., <https://doi.org/10.1016/j.psychres.2012.09.023>.
3. KITTIRATTANAPAIBOON, PHUNNAPA, et al. “Long-Term Outcomes in Methamphetamine Psychosis Patients after First Hospitalisation.” *Drug and Alcohol Review*, vol. 29, no. 4, 2010, pp. 456–461., <https://doi.org/10.1111/j.1465-3362.2010.00196.x>.
4. Glasner-Edwards, Suzette, and Larissa J. Mooney. “Methamphetamine Psychosis: Epidemiology and Management.” *CNS Drugs*, vol. 28, no. 12, 2014, pp. 1115–1126., <https://doi.org/10.1007/s40263-014-0209-8>.
5. Colton, Sharon. “The Web-Based Delphi Research Technique as a Method for Content Validation in HRD and Adult Education Research.” 2004, pp. 183–189.

Patient experiences in ED and perspectives on treatment.

Results from a qualitative study

Deborah Rinehart, PhD

deborah.Rinehart@dhha.org

BEATMeth



DENVER HEALTH™

est. 1860

FOR LIFE'S JOURNEY



Learning Objectives

- ❖ Describe patient's ED experiences and perspectives on entering treatment for methamphetamine addiction
- ❖ Apply these perspectives in designing care interventions

Formative Interviews

Individual qualitative interviews were conducted with patients with methamphetamine use disorder (MUD) to:

1. Learn more about individual's experiences with methamphetamine use, treatment, and experiences in emergency settings
2. Inform focus and logistics of the study care navigation intervention
3. Identify survey constructs of importance to this population

Methods




Recruitment

Purposeful sampling to recruit patients with MUD

Recruitment (July – Nov 2022) EHR to identify patients

1st Recruitment Phase

EHR data and study
flyers in specialty
treatment clinic.



Iterative review of data



2nd Recruitment Phase

Narrow focus on
recruiting patients from
PES and withdrawal
management services
with MIP flag.

Recruitment

2-week recruitment protocol



Final eligibility: current/former use of methamphetamines; English-speaking; willing to discuss MUD and treatment experiences

Interview Guide

One-time semi-structured qualitative interview – approximately 1 hour

Interview Guide:

- ED experience – particular to methamphetamine use
- Methamphetamine-induced psychosis (MIP) experience (2nd recruitment phase)
- History of substance use
- Substance treatment experience
- Treatment desires
- Intervention – services preferences following ED

Analysis

Rapid Assessment Process (Beebe, 2001)

- Iterative team approach
 - Met regularly to identify themes and topic saturation
- Audio-recorded interviews
- Interview summary



Interview Matrix



Thematic matrix

Thematic Matrix



ED Experience/CARES	MIP	History of Use	Treatment	Social networks	Treatment Desire	Intervention Design
<p>Lack of Compassion/Platinum Connection</p> <p>Overt Stigma (MC/SUD)</p> <p>Absent/Unhelpful connection to tx/resources</p> <p>Safety vs. Compassion</p> <p>Health concerns not addressed due to stigma</p> <p>Discharge plan lacking info/envo</p> <p>Need for trauma-informed care</p>	<p>Paramoia (Shadows people, hearing voices, hallucinations)</p> <p>Substance use as a means to escape harsh reality</p> <p>Trauma/Unhealthy Relationships</p> <p>Psychosis vs. Rate of Sleep, food?</p>	<p>Early onset of use (Cocaine, poly substance use)</p> <p>Substance use as a means to escape harsh reality</p> <p>Trauma/Unhealthy Relationships</p> <p>Psychosis vs. Rate of Sleep, food?</p>	<p>Barriers to complete discontinuation</p> <p>Triggers in the setting (e.g., No job)</p> <p>Positive exp. (CM or treatment if not tried)</p> <p>Bad experience w/ counselor and case manager in the past</p>	<p>Like peer groups (support)</p> <p>Dislike of peer groups (do not want to share info, want to find their dealer)</p> <p>Peers helpful to recovery vs. peers helpful to relapse</p>	<p>You have to want to get help!</p> <p>Barriers to seeking to get help</p> <p>Wish to know if it's there when ready</p> <p>Not interested in tx at this time</p>	<p>Intervention Design</p> <p>During ED (helpful for peer and case manager before discharge)</p> <p>Discharge/follow up (physical, follow up, hold onto resources)</p> <p>Retention/entry (incentives, focus on recovery maintenance)</p> <p>Qualities of CM (Calm, peer & professional, non-judgmental)</p>
<p>Major Themes</p>	<p>uncertainty of what is + if experienced</p> <p>complex tx - provider even MM being taken seriously</p>	<p>put descriptors in vs a theme. sets up context of our population</p> <p>described functionality + how dev. control life</p> <p>tally up age of use (background) - if in the piece of context - if occurring, avoid. MIND to</p>	<p>could always be in a not - what defined</p> <p>most had tx experience (family up)</p>	<p>May be put in tx section</p> <p>Peer Groups - NA. Need to take to how find right group not for all</p> <p>Share quotes.</p>	<p>When hand off</p> <p>During ED - staff better understand SUD + MH -</p> <p>Someone having convo throughout visit - reach out ahead of goals</p> <p>Discharge - diff frames (person, staff)</p> <p>Staff - explain to patients, more compassion, less judgement on SUDs</p> <p>Unonly way - knowing access where. Someone cases -> can't be</p> <p>If ready for tx -> get them in asap</p> <p>CM help w/ all areas will be helpful -> focus is recovery (then relation)</p> <p>Incentives as part of case management</p>	
<p>Minor Themes</p> <p>outlier #13 - PES great exp. (was high active + transportation)</p> <p>Highlight in manuscript</p> <p># had ED/CARES visit</p>					<p>had path of such a relapse</p> <p>few pts would not prefer peer support</p> <p>Cost of (stigma)</p>	

Please do not erase!
Thanks,
Dobbie, Aidan,
Karina

Results




Sample


N = 18

- 61% male
- 39% no steady place to live
- 72% homeless last year
- 28% currently on probation/parole


Enrollment Phase



Age




Race/Ethnicity




Substance Use and Treatment History

- Substance use initiation: 9-42 years of age
- 94% ever in substance use treatment

Treatment History



Age At Initiation Of Meth Use



Past Treatment Experiences

- Overall helpful: therapy, supportive/caring staff and resources
- Being with others who are struggling
- Lack support when get out of treatment
- Mixed experiences with peer groups
- Past barriers in retention
 - MOUD - low dose/restarts, how it makes you feel, wait times
 - Housing instability
 - Right level of treatment, length too short (payment)
 - Transportation
 - Lack of counselor time and connection

“They have the joy to help people. You can feel it in their spirit when you talk to them. You can feel it when you tell them what’s going on with you. You know it’s not just a job. They really are dedicated to helping people, keeping people sober, and helping them stay sober.”



Interviewee #9, female

“The therapeutic value of one addict helping another is unmatched”

“I’m a little leery about peer support, because we are all one step away from relapsing”

Interviewee #2, male



ED Experience

N= 6 had acute care visit related to meth use

Stigma due to substance use

- Treated poorly
- Health concerns minimized
- Lack of compassion/human connection

Perceived lack of information and communication

- Leads to feeling unsafe
- Exacerbates confusion

***“When you say it’s alcohol or meth...
they instinctively act like you’re a
criminal.”***

Interviewee #17, male

***“We don’t have time for tweakers right
now, we have people with real
problems.”***

Interviewee #2, male



“Tough to go into a building with a bunch of professionals, authoritative figures, especially with paranoia, stress and anxiety that comes with use...bad stigma attached with that kind of use [meth] so kind of treated me shitty, talking down to me, not caring about my needs.”

Interviewee #1, male

Methamphetamine Induced Psychosis (MIP)

Lack of understanding of MIP

- Not clear if someone can overdose on methamphetamines
- Symptoms can be result of substance use as well as lack of sleep, food and underlying mental health

Complicates treatment for mental health

- Symptoms not taken seriously
- Not remembering visit
- Extreme fear/paranoia
- “Shadow people”

“It went a really, really long time before me getting treatment because I did not realize I was in psychosis.”



Interviewee #5, female

Treatment Desire

Understand motivation to seek treatment

- Individuals must be ready for treatment to be effective
- Provide resources regardless of readiness

Motivators for treatment entry

- Gain control over their life again – rebuild
- Housing instability
- Family (especially children)
- Exhausted with lifestyle – lost everything

“Just letting them know that it’s out there when they’re in the ED... letting people know the resources are out there. Giving them resources, even if they throw it away, it would always be helpful to have something to call in a moment of desperation.”

Interviewee #2, male



“Being on the streets was one of the worst experiences that I have ever experienced, and that is what made me decide to get sober.”



Interviewee #12,
male

Recommendations for Intervention Design

Compassion and understanding from staff

- Less judgement
- Trauma-informed care principles

Address mental health and reasons for use

- Mental health not prioritized for those who use meth
- Need a more formalized MH assessment/treatment for MUD

Improve information channels

- Provide information through out the visit using different formats
- Provide information in context and have a conversation

“If you plant that seed, it’ll grow. It might not be an overnight, same day thing, but over time they might say ‘oh, maybe I do need some treatment. I keep showing up here.’”



Interviewee #10, male

Recommendations for Study Enrollment

- Approach patient before discharge but when they are “clear headed”
- After discharge: need to vary methods to find patient – letter, email, text

Enrollment in the overall study



- Warm hand off with linkage navigator
- Consistent engagement schedule
- If ready for treatment, connect as soon as possible
- Linkage across multiple areas is important – goal is recovery but need to meet patient where they are

Engagement with intervention



Recommendations for Treatment Entry/Retention

Proactive connections from care navigator

- Endorsed contingency management approach
- Support with barriers (transportation, duration to wait for entry, know where to get help, cost of treatment)
- Activate support networks, recovery maintenance channels, tools for healthy lifestyles

“I’ve been homeless and jobless so many times and that does not stop me from wanting to get help. If you make it horrible [treatment experience] that is what will stop me from getting help.”



Interviewee #7,
male

Qualities of Study Linkage Navigator

Genuine, compassionate, understanding, non-judgmental

Not solely focused on abstinence

Combination of peer and professional – ideal combination for most participants

Support with barriers (transportation, duration to wait for entry, know where to enter)

Potentially same gender (trauma history)

“Sometimes getting advice from people who have never, ever used, it’s almost not relevant to us. You don’t know... it might make you pay attention a little bit more [to a peer navigator] than working with someone who has never been through it.”



Interviewee #3, female

Limitations/Strengths

- In depth information and context
- Individuals in various stage of recovery
- Provided insight into experiences in acute care settings
- Small sample from one site

Final Takeaways/Summary

- Stigma
- Confusion and need for more explanation
- In person enrollment/warm hand off (paranoia hard to find post-discharge)
- At various stages of change for quitting/treatment – know someone is there

“I get a seat at the table. I can make my own decisions. I don’t have probation officers making my decisions. I don’t have to chase the dope man down. I don’t have to resort to nefarious acts to get money... I get to choose how I live, as opposed to letting my addiction choose how I live”

Interviewee #2, male



Questions/Comments?



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

BEATMeth



References

- Beebe J. *Rapid Assessment Process: An Introduction*. AltaMira Press; 2001.



Testing a new treatment paradigm: the BEAT Meth RCT

Alia Al-Tayyib, PhD
alia.altayyib@dhha.org

BEATMeth



DENVER HEALTH™

est. 1860

FOR LIFE'S JOURNEY



ASAM Annual Conference, April 15, 2023

Learning Objectives

- ❖ Describe the overall goal of BEAT Meth
- ❖ Describe goal of randomized controlled trial
- ❖ Understand barriers to treatment entry

BEATMeth

**Beginning Early and Assertive
Treatment for Methamphetamine Use
Disorder**

**Goal is to develop standard
work to identify, stabilize,
and connect patients to
treatment**



Beginning Early and Assertive Treatment for Methamphetamine Use Disorder (BEAT Meth)

A comprehensive systems-level secondary prevention strategy to prevent stimulant related overdoses (CDC R01 CE003363-01)

Overall goal: Evaluate the effectiveness of a secondary prevention strategy implemented at a systems-level to prevent stimulant related overdoses

Aim 1: Evaluate and optimize the treatment pathway for patients presenting to the ED with methamphetamine use disorder

- Develop standard work
- Build community partnerships
- Monitor fidelity
- Improve likelihood of patients entering treatment
- Create sustainable clinical workflows

Aim 2: Evaluate a linkage-to-care intervention to engage and retain patients in treatment

- Apply lessons from our current case management intervention for opioid use disorder and incorporate input from qualitative interviews
- Test a linkage-to-care intervention versus usual care in a randomized clinical trial (N=182)

Aim 3: Develop a methamphetamine use disorder continuum of care model to measure progression of patients with methamphetamine use disorder


- Create a framework to monitor the prevalence of methamphetamine use disorder
- Monitor patients' progress in treatment
- Direct resources to at-risk populations

Linkage-to-care

- ◆ Referral to treatment is a critical, yet often overlooked, component of clinical care
- ◆ Often neglected due to the amount of time and effort involved in making effective referral
- ◆ Complicated when patients have multiple barriers to treatment entry

Study Design

- ◆ Randomized controlled trial to assess acceptability, feasibility, and initial effectiveness of linkage navigation intervention
- ◆ Patients randomized with intervention (n=91) or usual care (n=91)
- ◆ Initial recruitment at CARES (Denver Health's withdrawal management services)



Eligibility

- ◆ Inclusion criteria:
 - ◆ 18 years of age or older
 - ◆ had a methamphetamine-related encounter at Denver Health
- ◆ Exclusion criteria:
 - ◆ under the age of 18
 - ◆ unable to provide informed consent
 - ◆ currently under residential involuntary psychiatric or substance treatment order
 - ◆ received any type of substance use treatment in the past 90 days

Intervention

- ◆ Dedicated Care Navigator
- ◆ Client-driven intake
- ◆ Trauma-informed and strengths-based approach
- ◆ Assesses significance of need in multiple domains
 - ◆ transportation, housing, insurance, legal, vital records, primary care, peer support, safety
- ◆ Incorporates elements of contingency management
 - ◆ Wheel spins and rewards for meeting with Care Navigator

Outcomes

- ◆ Primary outcome: continuation in treatment as defined as attendance at an outpatient addiction treatment appointment within 30 days of BEAT Meth discharge
- ◆ Secondary outcomes: treatment at 90 days, non-fatal overdose, fatal overdose, readmission, methamphetamine use, treatment readiness
- ◆ Community outcomes: police encounters, incarceration, paramedic trips

Final Takeaways

- ◆ Identifying effective strategies for helping patients enter and stay in treatment is essential.
- ◆ Addressing barriers to treatment entry is key.
- ◆ Recruitment is challenging.

Questions/Comments?



DENVER HEALTH

est. 1860

FOR LIFE'S JOURNEY

BEATMeth

